Conventionally fractionated external beam radiation therapy (EBRT) has a long-standing track record of safety and excellent treatment outcomes in the management of all prostate cancer risk groups.

Molecular diagnostics are rapidly evolving, leading to increased identification of previously 'rare' clinical entities.

Unfavorable intermediate-risk prostate cancer is commonly encountered in clinical practice but there is relatively little data focusing on treatment outcomes specific and limited to this patient cohort, with most clinical trials grouping these patients with favorable intermediate-risk disease or

There are multiple new developments in the treatment of breast cancer patients with radiation therapy, as well as ongoing developments in the use of breast IMRT. Practicing clinicians need to stay informed to improve outcomes among breast cancer patients.  

There have been many recent studies that further differentiate gynecologic cancers and their management relating to pathologic features, such as molecular status.

There are many strategies for managing brain mets with radiotherapy.

Over the past five years, multiple advances in diagnostic imaging, molecular stratification, and neurosurgical and radiotherapeutic approaches have changed the multi-disciplinary management of meningioma, the most common intracranial tumor.

The role of this activity reviews growing indications for radiation therapy for liver cancer, educates providers on radiation therapy options (SBRT, particle therapy) and the potential impact of hepatic reserve capacity on decision making, explores challenges and opportunities for clinical trials

There are many effective liver-directed loco-regional therapies for limited liver metastases including advanced techniques/approaches in surgery, radiation therapy, and interventional radiology.

Patients with head and neck cancer require specialized and multi-modality support during treatment. Providers may not be informed of the most up-to-date techniques to prevent and treat head and neck cancer radiation-related toxicity.